Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor, for the treatment of Acute Myeloid Leukemia (AML). Under the…

A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes validates Yatiri Bio’s platform as a breakthrough in oncology patient stratification.  Yatiri Bio, a precision medicine company utilizing an AI-driven proteomic platform (ProteoCharts™) to identify therapeutically…